Welcome to our dedicated page for Krystal Biotech SEC filings (Ticker: KRYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Wondering how a single 8-K can shift the outlook for Krystal Biotech’s redosable gene-therapy pipeline? SEC disclosures for cutting-edge biotech firms are thick with clinical jargon, FDA correspondence, and patent strategy—making it hard to spot what truly moves the stock.
Stock Titan’s AI turns that problem into a quick read. Our platform digests every Krystal Biotech quarterly earnings report 10-Q filing, flags fresh risk-factor language, and delivers sentence-level summaries so you can grasp revenue from VYJUVEK or cash runway in minutes. Need real-time alerts? We capture Krystal Biotech Form 4 insider transactions real-time so you can track when scientists or executives buy and sell. Even the dense 10-K becomes approachable—search �Krystal Biotech annual report 10-K simplified� and land here for instant context.
Browse every form in one place:
- 10-K & 10-Q � AI pinpoints R&D spend, clinical-trial milestones, and manufacturing scale-up plans.
- Form 4 � Follow Krystal Biotech executive stock transactions Form 4 to gauge insider sentiment.
- 8-K � Get Krystal Biotech 8-K material events explained, from FDA designations to licensing deals.
- DEF 14A � See the Krystal Biotech proxy statement executive compensation breakdown without combing through tables.
Whether you search �Krystal Biotech insider trading Form 4 transactions� or �understanding Krystal Biotech SEC documents with AI,� our expert analysis surfaces the numbers that matter. Save hours, compare filings historically, and rely on AI-powered highlights for confident decisions—all updated the moment EDGAR posts. That’s Krystal Biotech SEC filings explained simply.
Krystal Biotech (KRYS) 10-Q � Q2 2025 highlights
- Revenue: VYJUVEK® drove net product revenue to $96.0 m (+37% YoY); H1 2025 revenue reached $184.2 m (+60%).
- Profitability: Gross margin held at 93%. Income from operations leapt to $39.3 m (vs $8.6 m), thanks to higher sales and the absence of 2024 litigation charges. Net income was $38.3 m ($1.29 diluted EPS) versus $15.6 m ($0.53).
- Cash & Investments: Cash, cash equivalents and short-term investments rose to $682.0 m; total liquidity including long-term investments is $820.8 m. The company expects current resources to fund operations for �12 months.
- Expenses: R&D fell 8% YoY to $14.4 m as manufacturing timing shifted; SG&A climbed 27% to $35.2 m reflecting commercial build-out. No litigation settlement expense this quarter (-$12.5 m YoY).
- Balance sheet: Stockholders� equity surpassed $1.04 bn. Accounts receivable stood at $111.4 m, with ~78% concentrated in one customer.
- Pipeline progress: Multiple Phase 1/2 studies (KB407 CF, KB408 AATD, KB707 oncology, KB803 & KB801 ophthalmology) are enrolling; first EU & Japan launches of VYJUVEK expected H2 2025.
- Risks: DOJ subpoenas regarding genetic-testing program; outcome unknown. Heavy reliance on single product and customer concentration noted.
Krystal Biotech (KRYS) President of R&D, Director and 10% owner Suma M. Krishnan filed a Form 4 disclosing modest open-market sales executed on 9�10 July 2025 under a Rule 10b5-1 trading plan adopted 12 Sep 2024.
- Shares sold (reporting person): 7,000 common shares at weighted-average prices of $150.14�$151.39.
- Shares sold (spouse): 7,127 shares at $150.07�$151.39 under a separate 10b5-1 plan.
- Total shares disposed: 14,127, representing roughly 0.5% of their combined holdings.
- Remaining ownership: 1,456,711 shares directly; 90,000 via SMK Trust; 50,000 via Krishnan Family Trust; spouse retains 1,525,929 shares.
The transactions slightly reduce insider exposure yet leave the couple with an aggregate stake of about 3.1 million shares, signalling continuing alignment with shareholders. Because the sales were pre-scheduled, they carry limited information about the company’s near-term outlook.
FAQ
What is the current stock price of Krystal Biotech (KRYS)?
What is the market cap of Krystal Biotech (KRYS)?
